Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ulcerative Colitis
Research on ulcerative colitis described by J.W.H. Rios and colleagues
June 29th, 2009
According to a study from Barcelona, Spain, "The treatment of severe ulcerative colitis (UC) flares includes measures Such as hospitalization and intravenous steroids, Despite this. a quarter of patients are refractory to treatment. Given the availability of new therapeutic strategies in patients with steroid-refractory UC (cyclosporine, infliximab, apheresis, surgery) it is necessary to predict which treatment will be most effective for each patient." "to determine which clinical or biological factors discriminate the lack of response to cyclosporine in steroid-refractory UC. forty one flares of steroid-refractory UC in 35 patients treated with intravenous cyclosporine...
Source: Biotech Business Week (2009-06-29)
|
